PharmaLex Group , the leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced its intention to merge with Cpharm, the leading provider of pharmacovigilance and medical services in Australia and New Zealand.
The merger plan is an important step to expanding PharmaLex’s footprint in Australia and New Zealand through Cpharm’s expert capabilities in drug and device vigilance in the region, while offering complementary services and expanding the service portfolio of both companies.
For the past 20 years, Cpharm has been providing a wide range of pharmacovigilance, safety and risk management, medical information, material review and patient program services to support a wide range of clients – from start-ups to top-10 multinational pharmaceutical companies. With its headquarters in New South Wales, Australia, Cpharm’s team of 19 people has extensive experience in pharmacovigilance, medical information and managing patient programs.
“PharmaLex is a strong strategic partner for Cpharm and will provide our business with access to international clients, capacities and capabilities,” said Cpharm director and co-founder Josie Gabites. “It will also provide a good corporate culture for our team to expand their careers and will give our business strong support functions to facilitate sustainable growth of our business. For our clients, it will provide access to a wider range of services globally.”
“The merger with Cpharm will benefit both our businesses as well as our experts and our clients, allowing us to offer end-to-end solutions in the Australian market, while at the same time expanding our long and proven working relationship with Cpharm,” said Pharmalex Managing Director, Australia, Grant Bennett. “The agreement will enable PharmaLex to increase our coverage of pharmacovigilance and medical services in Australia and build interactions with the local client base to drive further growth for both organizations.”
